Real-World Success: Anti-CGRP mAbs Reduce Migraines

Research Summary

A study published in Neurology and Therapy explores real-world experiences with anti-CGRP monoclonal antibodies (mAbs) for migraine prevention in a large U.S. healthcare plan. This observational study, conducted at Sutter Health, involved 4683 eligible patients, with 484 completing a survey focusing on migraine characteristics and treatment outcomes. Among respondents, 62% reported fewer headaches, improved functionality, and enhanced quality of life with current mAb use compared to past users. Treatment persistence was notable, with 74% continuing mAb therapy at 6 months and 55% at 12 months. Current users expressed higher satisfaction than those who had discontinued treatment.

Study Details

📄 Title: Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.

👥 Research Team: Buse DC et al.

📚 Published In: Neurol Ther

📅 Publication Date: 2025 Dec 17

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.